TECHNOLOGY LICENSING OPPORTUNITY: NanoFET
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
Los Alamos National Laboratory (LANL) is offering a Technology Licensing Opportunity for its NanoFiber Engineered Therapeutics Platform (NanoFET). This platform provides a modular and adaptable scaffold for developing next-generation immunotherapies, targeting pharmaceutical and biodefense organizations.
Technology Overview
NanoFET merges self-assembling peptide nanofibers with interchangeable nanobody and peptide components, enabling rapid development of targeted treatments. It aims to bridge disease agents directly to a patient’s immune cells, addressing challenges in infectious diseases, cancer immunotherapy, and biodefense. The platform is at TRL 3 and has a U.S. Patent pending.
Key Advantages
- Modular Architecture: Allows rapid swapping of nanobodies and peptides for new disease targets without redesigning the core platform.
- Dual-Function Capability: Bridges disease agents directly to immune cells on a single construct.
- Adjuvant-Free Immune Activation: Self-assembling nanofibers inherently stimulate robust, innate immune responses.
- Small, Stable Targeting Molecules: Nanobodies are easier to produce and engineer than conventional full-size antibodies.
- High-Density Multivalent Display: Presents multiple antigens or functional components simultaneously, enhancing immune recognition.
- Compatibility with External Biologics: Enables partners to integrate their own AI-designed binders or proprietary targeting molecules.
Market Applications
Potential applications include Oncology (bispecific T-cell engagers, tumor-targeted immunotherapies), Infectious Disease Therapeutics (pan-influenza treatments, broad-spectrum antiviral and antibacterial countermeasures), Biodefense and Military Medicine (medical countermeasures for warfighters), Vaccine Development (multiantigen vaccine platforms), and Pharmaceutical Biologics and Drug Delivery (nanobody-drug conjugate scaffolds).
Contract & Timeline
- Type: Special Notice - Technology Licensing Opportunity
- Response Date: December 18, 2026
- Published Date: June 17, 2026
- Set-Aside: None
- Place of Performance: Los Alamos, NM
Additional Information
This is not a call for external services for the development of this technology. Interested parties should contact LANL's licensing program for specific discussions regarding patented and patent-pending inventions and copyrighted software.
Contact: Caleb Ledgerwood / Lindsay Augustyn at licensing@lanl.gov.